latent GDF-8

latent GDF-8

latent GDF-8 詳細

Molecule Name
Growth/differentiation factor 8
分子の別称
latent GDF-8
Drug Development Progress
治験薬の数6
市販薬剤の数0
研究&開発段階NDA/BLA
ターゲットの別称
MSTN,GDF-8,GDF8,Growth Differentiation Factor 8,MSLHP,Myostatin,Growth/Differentiation Factor 8
バックグランド
Growth differentiation factor 8 (GDF8), also known as myostatin, is a unique member of the transforming growth factor-β superfamily that is expressed in human granulosa cells and has important roles in regulating a variety of ovarian functions. GDF8 acts as a negative regulator of skeletal muscle growth and differentiation. In addition to the expression in the musculoskeletal system, GDF8 is also expressed in various tissues, including the reproductive system.

お問い合わせ

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Talditercept alfaRO-7239361; BMS-986089; RG-6206; BHV-2000Phase 3 ClinicalBristol-Myers Squibb Company
Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Muscular Atrophy, Spinal
詳細
RO-7204239GYM-329; RO-7204239; RG-6237; RG-70240Phase 3 ClinicalF. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd
Muscular Dystrophy, Facioscapulohumeral; Muscular Atrophy, Spinal
詳細
TrevogrumabREGN-1033; REGN1033; SAR-391786; GDF8Phase 2 ClinicalRegeneron Pharmaceuticals Inc
Myositis, Inclusion Body; Obesity; Sarcopenia
詳細
AAV1-FS344AAV1-Follistatin; AAV1-FS344Phase 2 ClinicalNationwide Children'S Hospital
Becker muscular dystrophy; Myositis, Inclusion Body; Muscular Dystrophy, Duchenne
詳細
KER-065KER-065; RKER-065Phase 1 ClinicalKeros Therapeutics Inc
Neuromuscular Diseases; Obesity
詳細
HS135HS-135Phase 1 Clinical35Pharma Inc
Hypertension, Pulmonary; Heart Failure, Diastolic; Pulmonary Arterial Hypertension
詳細
Customer Reviews